Antifosfolipid Sendromu Tanısının Değerlendirilmesi

Yöntem Referans Değer Unit
Kardiolipin IgG otoantikorları EIA <11 GPLU/ml
Kardiolipin IgM otoantikorları EIA <10 MPLU/ml
Kardiolipin IgA otoantikorları EIA <13 APLU/ml
Fosfatidiletanolamin IgG otoantikorları EIA <2.0
Fosfotidiletanolamin IgA otoantikorları EIA <2.0
Klinik kullanımı :
Fosfolipid antikorları; SLE, Lupus benzeri Hastalıklarla ve
Antifosfolipid Sendromu (APS) ile ilişkilidir. Klinik olarak genelde;
Arteriyel ve derin ven trombusları, Spontan düşük tekrarı, Nörolojik
ve kardiolojik bozukluklar, Trombositopeni gibi bozukluklar ile
ortaya çıkmaktadır.
Kaynaklar ve Referanslar
- [1]Murvai VR, GaliÈ™ R, Panaitescu A, et al. “Antiphospholipid syndrome in pregnancy: a comprehensive literature review.”. BMC pregnancy and childbirth. 2025. PMID: 40128683. PubMed →
- [2]Barbhaiya M, Zuily S, Naden R, et al.. “2023 ACR/EULAR antiphospholipid syndrome classification criteria.”. Annals of the Rheumatic Diseases. 2023. PMID: 37640450. PubMed →
- [3]Heikal N, Martins TB, White SK, et al. “Laboratory Evaluation of Antiphospholipid Syndrome.”. American journal of clinical pathology. 2019. PMID: 31305881. PubMed →
- [4]Miyakis S, Lockshin MD, Atsumi T, et al.. “International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).”. Journal of Thrombosis and Haemostasis: JTH. 2006. PMID: 16420554. PubMed →
- [5]Tebo AE. “Laboratory Evaluation of Antiphospholipid Syndrome: An Update on Autoantibody Testing.”. Clinics in laboratory medicine. 2019. PMID: 31668269. PubMed →
- [6]Devreese KMJ, Bertolaccini ML, Branch DW, de Laat B, Erkan D, Favaloro EJ, Pengo V, Ortel TL, Wahl D, Cohen H. “An update on laboratory detection and interpretation of antiphospholipid antibodies for diagnosis of antiphospholipid syndrome: guidance from the ISTH-SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies.”. Journal of Thrombosis and Haemostasis: JTH. 2024. PMID: 39510414. PubMed →


